Psychological adjustment to initial treatment for low-risk thyroid cancer: Preliminary study.
active surveillance
immediate surgery
low risk
papillary microcarcinoma
thyroid cancer
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
revised:
17
10
2022
received:
15
06
2022
accepted:
21
11
2022
pubmed:
11
12
2022
medline:
4
1
2023
entrez:
10
12
2022
Statut:
ppublish
Résumé
Low-risk papillary thyroid carcinoma (LR-PTC) can be managed by immediate surgery (IS) or active surveillance (AS). We compare the psychological impact of these treatments on patients with LR-PTC. Psychological data were collected over 1 year, with assessments at the time of treatment decision (T1), at 6 months (T2) and 12 months (T3) follow-up. Assessments included 13 validated psychological tools. Of 27 enrolled patients, 20 chose AS and 7 chose IS. The average times to T2 and T3 were 5.7 and 11.3 months, respectively. For both groups, Impact of Events Scale scores significantly decreased (p = 0.001) at T2, and depressive/anxiety symptoms remained low. This study demonstrates the feasibility of assessing psychological outcomes among patients treated for LR-PTC. Further studies are needed to evaluate the impact of AS versus IS on quality of life and changes that patients experience over longer time periods following their treatment decision.
Sections du résumé
BACKGROUND
Low-risk papillary thyroid carcinoma (LR-PTC) can be managed by immediate surgery (IS) or active surveillance (AS). We compare the psychological impact of these treatments on patients with LR-PTC.
METHODS
Psychological data were collected over 1 year, with assessments at the time of treatment decision (T1), at 6 months (T2) and 12 months (T3) follow-up. Assessments included 13 validated psychological tools.
RESULTS
Of 27 enrolled patients, 20 chose AS and 7 chose IS. The average times to T2 and T3 were 5.7 and 11.3 months, respectively. For both groups, Impact of Events Scale scores significantly decreased (p = 0.001) at T2, and depressive/anxiety symptoms remained low.
CONCLUSIONS
This study demonstrates the feasibility of assessing psychological outcomes among patients treated for LR-PTC. Further studies are needed to evaluate the impact of AS versus IS on quality of life and changes that patients experience over longer time periods following their treatment decision.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
439-448Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Brito JP, Moon JH, Zeuren R, et al. Thyroid cancer treatment choice: a pilot study of a tool to facilitate conversations with patients with papillary microcarcinomas considering treatment options. Thyroid. 2018;28:1325-1331.
Davies L. Overdiagnosis of thyroid cancer. BMJ. 2016;355:i6312.
Tuttle RM, Fagin JA, Minkowitz G, et al. Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance. JAMA Otolaryngol Head Neck Surg. 2017;143:1015-1020.
Sugitani I, Toda K, Yamada K, Yamamoto N, Ikenaga M, Fujimoto Y. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg. 2010;34:1222-1231.
Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg. 2010;34:28-35.
Chou R, Dana T, Haymart MR, et al. Active surveillance versus thyroid surgery for differentiated thyroid cancer: a systematic review. Thyroid. 2022;32(4):351-367.
Ito Y, Miyauchi A, Kihara M, Higashiyama T, Kobayashi K, Miya A. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid. 2014;24:27-34.
Ito Y, Uruno T, Nakano K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid. 2003;13:381-387.
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1-133.
Sawka AM, Ghai S, Yoannidis T, et al. A prospective mixed-methods study of decision-making on surgery or active surveillance for low-risk papillary thyroid cancer. Thyroid. 2020;30:999-1007.
Hughes DT, Reyes-Gastelum D, Ward KC, Hamilton AS, Haymart MR. Barriers to the use of active surveillance for thyroid cancer: results of a physician survey. Ann Surg. 2020;276:e40-e47.
Jensen CB, Saucke MC, Pitt SC. Active surveillance for thyroid cancer: a qualitative study of barriers and facilitators to implementation. BMC Cancer. 2021;21:471.
Haymart MR, Miller DC, Hawley ST. Active surveillance for low-risk cancers-a viable solution to overtreatment? N Engl J Med. 2017;377:203-206.
Nickel B, Brito JP, Moynihan R, Barratt A, Jordan S, McCaffery K. Patients' experiences of diagnosis and management of papillary thyroid microcarcinoma: a qualitative study. BMC Cancer. 2018;18:242.
Davies L, Roman BR, Fukushima M, Ito Y, Miyauchi A. Patient experience of thyroid cancer active surveillance in Japan. JAMA Otolaryngol Head Neck Surg. 2019;145:363-370.
Yoshida Y, Horiuchi K, Okamoto T. Patients' view on the management of papillary thyroid microcarcinoma: active surveillance or surgery. Thyroid. 2020;30:681-687.
Jeon MJ, Lee YM, Sung TY, et al. Quality of life in patients with papillary thyroid microcarcinoma managed by active surveillance or lobectomy: a cross-sectional study. Thyroid. 2019;29:956-962.
Nakamura T, Miyauchi A, Ito Y, et al. Quality of life in patients with low-risk papillary thyroid microcarcinoma: active surveillance versus immediate surgery. Endocr Pract. 2020;26:1451-1457.
Moon JH, Kim JH, Lee EK, et al. Study protocol of multicenter prospective cohort study of active surveillance on papillary thyroid microcarcinoma (MAeSTro). Endocrinol Metab (Seoul). 2018;33:278-286.
Kong SH, Ryu J, Kim MJ, et al. Longitudinal assessment of quality of life according to treatment options in low-risk papillary thyroid microcarcinoma patients: active surveillance or immediate surgery (interim analysis of MAeSTro). Thyroid. 2019;29:1089-1096.
Marteau TM, Bekker H. The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). Br J Clin Psychol. 1992;31:301-306.
Beck AT, Steer RA, Brown G. Manual for the Beck Depression Inventory-II. Psychological Corporation; 1996.
Weiss DS. The impact of event scale: revised. In: Wilson JP, Tang CS-K, eds. Cross-Cultural Assessing Psychological Trauma and PTSD. Springer; 2007:219-238.
Watt T, Bjorner JB, Groenvold M, et al. Development of a short version of the thyroid-related patient-reported outcome ThyPRO. Thyroid. 2015;25:1069-1079.
Cella D, Riley W, Stone A, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol. 2010;63:1179-1194.
Devins GM. Using the illness intrusiveness ratings scale to understand health-related quality of life in chronic disease. J Psychosom Res. 2010;68:591-602.
Meyer TJ, Miller ML, Metzger RL, Borkovec TD. Development and validation of the Penn State Worry Questionnaire. Behav Res Ther. 1990;28:487-495.
Renna ME, Rosie Shrout M, Madison AA, et al. Worry and rumination in breast cancer patients: perseveration worsens self-rated health. J Behav Med. 2021;44:253-259.
Carleton RN, Norton MA, Asmundson GJ. Fearing the unknown: a short version of the Intolerance of Uncertainty Scale. J Anxiety Disord. 2007;21:105-117.
Tan HJ, Marks LS, Hoyt MA, et al. The relationship between intolerance of uncertainty and anxiety in men on active surveillance for prostate cancer. J Urol. 2016;195:1724-1730.
Rini C, Jandorf L, Goldsmith RE, Manne SL, Harpaz N, Itzkowitz SH. Interpersonal influences on patients' surgical decision making: the role of close others. J Behav Med. 2011;34:396-407.
Revenson TA, Griva K, Luszczynska A, et al. Caregiving in the Illness Context. Houndmills, Basingstoke, Hampshire. Palgrave Macmillan; 2016.
Violette PD, Agoritsas T, Alexander P, et al. Decision aids for localized prostate cancer treatment choice: systematic review and meta-analysis. CA Cancer J Clin. 2015;65:239-251.
Aning JJ, Wassersug RJ, Goldenberg SL. Patient preference and the impact of decision-making aids on prostate cancer treatment choices and post-intervention regret. Curr Oncol. 2012;19:S37-S44.
Brehaut JC, O'Connor AM, Wood TJ, et al. Validation of a decision regret scale. Med Decis Making. 2003;23:281-292.
O'Connor AM. Validation of a decisional conflict scale. Med Decis Making. 1995;15:25-30.
Koshkina A, Fazelzad R, Sugitani I, et al. Association of patient age with progression of low-risk papillary thyroid carcinoma under active surveillance: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg. 2020;146:552-560.
Ho AS, Luu M, Zalt C, et al. Mortality risk of nonoperative papillary thyroid carcinoma: a corollary for active surveillance. Thyroid. 2019;29:1409-1417.
Megwalu UC. Observation versus thyroidectomy for papillary thyroid microcarcinoma in the elderly. J Laryngol Otol. 2017;131:173-176.
Moon JH, Ryu CH, Cho SW, et al. Effect of initial treatment choice on 2-year quality of life in patients with low-risk papillary thyroid microcarcinoma. J Clin Endocrinol Metab. 2021;106:724-735.
Sawka AM, Ghai S, Tomlinson G, et al. A protocol for a Canadian prospective observational study of decision-making on active surveillance or surgery for low-risk papillary thyroid cancer. BMJ Open. 2018;8:e020298.